Home › Free Stock Grades › PRME
Prime Medicine, Inc. (PRME) Stock Grade
PRME · Healthcare
A-
Market Cap
$516.2M
P/E Ratio
—
Revenue Growth (YoY)
+55.3%
Net Margin
-4342.4%
Return on Equity
—
Dividend Yield
None
About Prime Medicine, Inc.'s fundamentals
Prime Medicine is a biotechnology company with a market capitalization of $516.2 million that is experiencing significant revenue growth of 55.3% year-over-year, indicating expanding business activity. However, the company operates at a substantial loss, with a net margin of -4342.4%, and reported a net loss in its latest annual statement, meaning it is not yet profitable. The company does not pay a dividend, which is typical for early-stage biotech firms reinvesting capital into research and development.